-
OncoSec Medical’s TAVO-EP Combo Misses Primary Endpoint in Melanoma Trial
•
US-based OncoSec Medical Inc., (OTCMKTS: ONCSQ), majority-owned by China-based Grand Pharmaceutical Group Ltd (HKG: 0512), has revealed disappointing data from a crucial pivotal Phase II trial assessing the firm’s lead DNA drug candidate TAVO-EP (tavokinogene telseplasmid) combined with the programmed death-1 (PD-1) monoclonal antibody Keytruda (pembrolizumab) as a treatment for…
-
Legend Biotech Corporation Appoints Industry Veterans to Strategic Advisory Board
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced the formation of a strategic advisory board and the appointments of Michel Vounatsos, former CEO of Biogen Inc., and John Maraganore, PhD, former CEO of Alnylam Pharmaceuticals, as advisors. Mr. Vounatsos and Dr. Maraganore will collaborate closely with Legend Biotech’s leadership team…
-
Beijing-Tianjin-Hebei Alliance Completes VBP Tender for Coronary Intervention Devices with 78.29% Price Cut
•
The Beijing-Tianjin-Hebei “3+N” allied region has completed a volume-based procurement (VBP) tender for coronary catheters, guide wires, and coronary dilation balloons, with the results now published. This comprehensive coverage of consumables used during coronary interventional surgery marks a significant step in the regional VBP initiative. The latest round saw an…
-
Jacobio Pharma Receives Approval for Phase I/IIa Study of LIF mAb in Advanced Solid Tumors
•
China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to conduct a Phase I/IIa clinical study for its leukemia inhibitory factor (LIF) monoclonal antibody (mAb) in patients with advanced solid tumors. LIF as a Target for KRAS-driven TumorsLIF is a key target in KRAS-driven tumors, including pancreatic and…
-
Nanjing Zenshine Pharmaceuticals’ ZX-7101A Meets Primary Endpoint in Phase II Influenza Study
•
China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd announced that a Phase II clinical study for its anti-influenza drug ZX-7101A in adult simple influenza has successfully reached the primary endpoint. Design and Results of the Phase II/III StudyThe multi-center, randomized, double-blind, placebo-controlled Phase II/III study is designed to…
-
WuXi Advanced Therapies (WuXi ATU) Closes Manufacturing Facilities in Shanghai Due to Market Changes
•
Media reports indicate that WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused Contract Testing, Development, and Manufacturing Organization (CTDMO) unit of Wuxi Apptec (SHA: 603259, HKG: 2359), has closed its commercial-scale manufacturing facilities in Lingang, Shanghai. This decision was made in light of changing external market conditions, as…
-
Shenzhen Hepalink’s Subsidiary Techdow USA Secures Distribution Rights for ANDA-Approved Drug
•
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its wholly owned subsidiary, Techdow USA Inc., has entered into a distribution and supply agreement with compatriot firm Chia Tai Tianqing. The agreement centers on Chia Tai Tianqing’s ANDA-approved fosaprepitant dimeglutide in the United States, with Techdow being…
-
SPH CanSinoBio Suspends COVID-19 Vaccine Production for 180 Days Amid Market Shifts
•
SPH CanSinoBio, a joint venture between Shanghai Pharmaceuticals Group (SHA: 601607, HKG: 2607) and CanSino Biologics (SHA: 688185, HKG: 6185), has reportedly decided to halt production of COVID-19 vaccines as of April 4 for a period of 180 days, citing changes in the external market environment. The company, which is…
